Serum Fetuin-A Levels in Patients with Bilateral Basal Ganglia Calcification

摘要

Highlights ? We detected lower levels of serum fetuin-A in patients with basal ganglia calcification. ? In all subgroups, mean fetuin-A levels were significantly lower in patients with basal ganglia calcification. ? Higher serum fetuin-A levels should be measured in patients with basal ganglia calcification. ? We believe that the measurement of serum fetuin-A may play a role in the prediction of basal ganglia calcification as a biomarker. Abstract Background and Purpose The idiopathic basal ganglia calcification (Fahr syndrome) may occur due to senility. Fetuin-A is a negative acute phase reactant which inhibits calcium-phosphorus precipitation and vascular calcification. In this study, we aimed to evaluate whether serum fetuin-A levels correlate with bilateral basal ganglia calcification. Method Forty-five patients who had bilateral basal ganglia calcification on brain CT were selected according to the inclusion and exclusion criteria, and 45 age and gender-matched subjects without basal ganglia calcification were included for the control group. Serum fetuin-A levels were measured from venous blood samples. All participants were divided into two groups; with and without basal ganglia calcification. These groups were divided into subgroups regarding age (18–32 and 33–45 years of age) and gender (male, female). Results We detected lower levels of serum fetuin-A in patients with basal ganglia calcification compared with the subjects without basal ganglia calcification. In all subgroups (female, male, 18–32 years and 33–45 years), mean fetuin-A levels were significantly lower in patients with basal ganglia calcification (p?=?0.017, p?=?0.014, p?=?0.024, p?=?0.026, p?=?0.01 respectively). And statistically significantly lower levels of fetuin-A was found to be correlated with the increasing densities of calcification in the calcified basal ganglia group (p-value: Conclusion Considering the role of fetuin-A in tissue calcification and inflammation, higher serum fetuin-A levels should be measured in patients with basal ganglia calcification. We believe that the measurement of serum fetuin-A may play a role in the prediction of basal ganglia calcification as a biomarker.